Treatment with these drugs also resulted in a decrease in SERPINA1, APOC3, CD99, CPSF6, CRNN, SERPINA6, HBA2, MB, VGF, PIGR, and TTR urinary peptides, indicating a potential treatment benefit as many of these proteins are found at increased levels in T2DM patients. This evidence concerns the gene APOC3 and type 2 diabetes mellitus.